In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Tixagevimab-Cilgavimab for infection prevention (NEJM)
• Ivermectin for outpatient infection treatment (medRxiv)
• Symptom rebound after PAXLOVID treatment (IDSA)
• Bamlanivimab minimally impacts immune response to vaccination (Sci Transl Med)
• In-hospital morality among infected patients (IDSA)
• Casirvimab/Imdevimab & Remdesivir for infected B-cell depleted patients (IDSA)
• PAXLOVID patient eligibility screening checklist (FDA)
• Remdesivir fact sheet for providers (Veklury) 
• Bebtelovimab fact sheet for providers (FDA)
• Residual viral antigen in patients post infection (IDSA)
• Rheumatic symptoms following infection (IDSA)
• Contribute to FIMRC fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 910
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]